Richard J. Booth

Learn More
The protein kinase checkpoint kinase 1 (Chk1) has been implicated as a key regulator of cell cycle progression and DNA repair, and inhibitors of Chk1 (e.g., UCN-01 and EXEL-9844) potentiate the cytotoxic actions of chemotherapeutic drugs in tumor cells. We have examined the ability of PD-321852, a small-molecule Chk1 inhibitor, to potentiate(More)
Call centers have relied historically, on Erlang-C based estimation formulas to help determine number of agent positions and queue parameters. These estimators have worked fairly well in traditional call centers, however recent trends such as skill-based routing, electronic channels and interactive call handling demand more sophisticated techniques (see(More)
Altiratinib (DCC-2701) was designed based on the rationale of engineering a single therapeutic agent able to address multiple hallmarks of cancer (1). Specifically, altiratinib inhibits not only mechanisms of tumor initiation and progression, but also drug resistance mechanisms in the tumor and microenvironment through balanced inhibition of MET, TIE2(More)
  • 1